J o u r n a l P r e -p r o o f Highlights  Our study thresholds stride time variations during walking at 2.34%  Uncertainty bounds [1.92%, 2.76%] provides a robust benchmark for discriminating pathological from healthy asymptomatic performance with an overall accuracy of 75%.
Introduction
The effective performance of activities of daily living such as standing, walking or reaching is fundamental to leading an independent life. Walking specifically, is an essential locomotor activity that requires effective regulation between central and peripheral nervous, and musculoskeletal system resources allowing us to synergize the movement of limbs both spatially (inter-limb coordination) and temporally (rhythmicity -constancy in step repetitions), such that we can maintain our balance (regulation of the centre of mass over the base of support) (1) (2) (3) . In addition, these resources are needed to negotiate obstacles in the environment (obstacle avoidance) and to respond to perturbations to the moving body (4, 5) . Due to the continuous regulation of these neural resources, as well as the noise inherently present in both sensory and motor signals (6) (7) (8) (9) , motor output fluctuates around a target or desired level, termed motor output or Movement Variability (MoV - (10, 11) ).
The ability to walk in a stable manner declines with age and pathology, adversely affecting health-related quality of life (12, 13) . Furthermore, movement deficits require individuals to perform activities near their maximal effort (6, 14, 15) , thus continually challenging them physically (but also cognitively (16, 17) ) and, in many cases, leading to adverse events such as injurious falling. Recent evidence shows that elderly adults produce repetitive movements such as walking with greater MoV, possibly due to the loss in strength and flexibility (18) as well as the decline in walking speed (19) . Interestingly, MoV is even greater in individuals that are at a high risk of falling (20, 21) , or suffer from neurological disorders affecting motor function (hereinafter referred to as "movement disorders") such as Parkinson's disease (PD), Multiple Sclerosis, or Huntington's disease (22) (23) (24) (25) .
It is likely that an optimal window of MoV characterises asymptomatic individuals, and differentiates healthy from pathological movement function (6, 10, (26) (27) (28) . In general, below this window, movement is likely to become rigid (system with limited flexibility to adjust to internal and external perturbations), while MoV above the optimum would bring the system closer to its limits of stability (generally provided by the feet in contact with the ground that form the base-J o u r n a l P r e -p r o o f of-support -see (29) for details), with both extremes indicating deficits in movement performance (27) . Such an interpretation might appear in line with contemporary theoretical frameworks (cf. proposed by (30) , but also confirmed by (31) ), which hypothesize that movement tasks are likely adapted and executed (i.e. the level that one should aim for (30) ) by optimizing accuracy, while requiring minimal control effort. The threshold probed within this study however, is conceptually different in that it reflects an optimal boundary identified across multiple studies that differentiates healthy from pathological gait. Such a threshold would allow the possible use of MoV as an effective biomarker for assessing an individual's neuro-motor status. A comprehensive knowledge of MoV with clear definitions for asymptomatic task performance in both temporal and spatial domains could allow different metrics of variability to be established as intrinsic features of performance (signatures) to associate an individual's quality of movement with their underlying neural status. In essence, by identifying the optimal thresholds for benchmarking motor signatures, we envisage prioritising and formalising potentially useful movement-based biomarkers for neurological disorders (32, 33) . As such, a well-defined biomarker, or combination thereof, can address the persistent clinical need for early identification of movement disorders (screening) as well as for evaluating the effectiveness of therapies for returning individual patients to some level of independent living.
In a previous systematic review (26) , we investigated the thresholds between healthy asymptomatic and pathological magnitudes of task variability, and concluded that, for the parameter "variability of stride time" (STV; evaluated as the coefficient of variation, CV of stride time), upper thresholds of 2.6%CV discriminated pathological from healthy adults performance. Furthermore, 1.1%CV was identified as the lower threshold for healthy variability in adults.
Although the systematic review approach was comprehensive, a very large sample of clinical trials, each consisting of a suitable number of subjects, is clearly needed in order to better estimate the true value of the boundaries. Until then, such a pool of information will neither be reliable nor robust, meaning that the inclusion of any further clinical trial data would have sufficient relative weight to influence the existing evidence on optimal levels of variability.
Therefore, it is critical to determine methods that are able to absorb the changes such that the estimated boundary levels remain robust and meaningful in light of additional evidence. One such J o u r n a l P r e -p r o o f approach involving the estimation of probabilistic thresholds has been proposed previously in other domains, but never used in the clinical context of movement signatures (34) . As a result, due to the growing recognition of metrics of MoV for assessment in clinical settings, a full and complete study evaluating thresholds between healthy asymptomatic and pathological task variability, is timely.
The selective effects of movement disorders such as PD on different neurological structures (consequently impairments may also be variable) highlight the importance of holistically understanding the interplay between various locomotor characteristics that are critical during walking (22) . However, due to the conventional subjective approach of preselecting parameters in a somewhat arbitrary manner (e.g. STV is reported far more than any other spatio-temporal parameter in the literature (26) , possibly due to its ease of measurement), the complex interactions between multiple different features of walking remain largely unexplored. Such subjective practices therefore hinder an accurate characterization of movement deficits in both clinical cohorts and on an individual basis. Thus, an understanding of how multiple signatures of gait are regulated would lay the foundations for unravelling the neuromuscular mechanisms that are involved in not only walking, but also movement in general (35) (36) (37) . With a vision to distinguish healthy asymptomatic from pathological gait performance in a holistic manner, we therefore aim to broaden our knowledge of optimal windows of variability (originally investigated only for stride time (26)) by estimating the optimal thresholds for all commonly reported characteristics of walking.
The aim of this review was therefore to firstly provide current state-of-the-art and reliable evidence on magnitude of MoV in healthy walking behaviour, but also to exploit a probabilistic approach for improving the robustness of the optimum window of MoV. Finally, this paper presents a case study involving a statistical model for investigating motor deficits in PD patients using the optimum thresholds identified in the review, including preliminary data from a retrospective case-control study.
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Methods

Search strategy and study selection
The literature search and selection strategy (Supp. Methods 1) in the original systematic review Participants -cohort of healthy adults and a cohort of patients with a neurological pathology, and
3) Task -walking on a treadmill or overground at a comfortable or self-selected walking speed.
The search was further restricted to peer reviewed articles published in the English language. An exhaustive list of exclusion criteria is presented as supplementary material (Supp. Methods 2.
Exclusion criteria). Two of the authors (DK and MG) performed the literature search and screened the studies at each stage of the review; any disagreement was resolved by consensus (together with NBS). The study was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA, see Figure 1 ) and the PRISMA checklist is provided as supplementary material. The literature search identified 11,111 potentially relevant articles. After the removal of duplicates (n=2384) and articles rejected based on title or abstract (n=8543), 184 articles were included for full text screening. During this process, a further 163 articles were excluded. Finally, 21 studies were included containing a total sample of 752 patients and 608 healthy asymptomatic participants over and above the 1657 patients and 1915 healthy asymptomatic participants from the original study (26) . The characteristics of all included studies is presented in a supplementary 
Risk of bias assessment
Two authors (DK and NBS) independently assigned the risk of bias quality scores to the studies with the use of the MINORS tool. Each study was assessed as having high, unclear or low risk of bias on all items (scored from 0 to 2 respectively with an ideal global score of 18) included in the original checklist (three items: Unbiased Assessment of the Study Endpoint, Follow-up period appropriate to the aim of the study, and Loss to follow up less than 5% were considered irrelevant and were excluded). Any discrepancies between reviewers were resolved through consensus. The results are presented in a supplementary table (Supplementary Table 2 ).
Data Analysis and Synthesis
We used measures of variability of spatio-temporal parameters of walking reported through coefficient of variation (CV) for both healthy asymptomatic and pathological cohorts. An effect size (ES -the difference between the means of the pathological and healthy asymptomatic control groups over the pooled standard deviation, which was additionally corrected for sample size to provide Hedges' g) for each study was used to express the difference between cohorts in a standardised manner. The group averages for each gait parameter from all studies were then combined by calculating a pooled effect size using standard error as a weighting factor (in order to minimize the risk of overestimation). Heterogeneity among the included studies was assessed and interpreted using I 2 statistics (according to the Cochrane guidelines (38) ). Additionally, potential publication bias was assessed through visual inspection of the funnel plot with effect sizes and standard error of the effect estimate. In order to estimate the upper boundary of the performance window, all studies that exhibited a positive ES were selected for the logistic regression. Similarly, studies that revealed a negative ES formed the basis for estimating the lower boundary (26) .
A generalized linear mixed model fit using maximum likelihood criteria (with Laplace approximation to integrate the likelihood function (39) ) was used to model the log odds of the binary outcome (0 for healthy asymptomatic, 1 for pathological) as a linear combination of the predictor variable (CV gait parameter) and the study index (random effects). As the means of the healthy asymptomatic and pathological groups for a particular walking parameter originating J o u r n a l P r e -p r o o f from the same study could be correlated to each other due to the inherent study design and experimental protocol, a mixed-effects model was used to account for the random effect of the paired data (healthy asymptomatic vs. pathological) within each included study and also accounting for heterogeneity in meta-analysis.
The logistic model (with random effect for the study index) is given by:
where p i is the probability that the observation belonged to a particular cohort given the predictor variable, (gait parameter), and the study index, ; 0 and 1 are coefficient estimates of the regression model estimated using maximum likelihood (see Supplementary.
Figures 1-7). Finally, in order to test whether the model with the predictor variable (model with
the alternate hypothesis wrt coefficient 1 ) fits significantly better than a null model (model with the null hypothesis wrt 1 ), we evaluated Bayes Factor using BIC (where BIC = BICH1 -BICH0 and BIC is the Bayesian Information criteria -please refer to (43) ).
The discriminatory accuracy of our model was assessed using the receiver operating characteristic (ROC) curve obtained by mapping sensitivity versus specificity for all possible values of the cutoff point between pathology and healthy. Here, sensitivity (True Positives) was defined as the probability of correctly classifying an individual as pathological, while specificity was the probability of correctly classifying an individual as healthy asymptomatic (True Negative) (40) . The optimality criterion was given by:
The optimum cut-off probability point, , was obtained from Eqn 2 as the point minimizing the Euclidean distance between the ROC curve and the (1,1) coordinate on the ROC plane (40) -see 
Probabilistic thresholds
Optimum separation between healthy asymptomatic and pathological motor performance for any physiological parameter (in our case gait variability) will approach the "true value", only when estimated using a sufficiently large number of clinical trials with adequate sample of healthy and pathological participants. Such a measure can only be informative when the mean is reported together with its standard error, hence providing the basis for confidence levels (or uncertainty)
to be evaluated (41) . In the present study, the standard error (SE) was estimated as probability boundaries (See Supp. Figure 15 -21) of the evaluated optimal threshold ( ) via Eqns. 1 -3, which then provided a more systematic and reliable estimate of the window of healthy physiological gait performance. SEs were evaluated using the Delta Method involving a first-order
Taylor approximation (42) , which is given by: Case study: Experimental approach to demonstrate the application of optimal thresholds in the clinical context.
In an attempt to demonstrate how the optimum thresholds can be used to provide rapid and robust indications on healthy versus pathological gait performance, we exemplarily applied the synthesised evidence to preliminary movement data from a retrospective case-control study.
Twenty elderly volunteers including 10 patients with PD (PwPD) with a mean(SD) age of 59 (6) written, informed consent approved by the local ethics committee (registration number: 2015-00141) prior to participation. The participants were requested to walk continuously in a path shaped as an "8" in the laboratory for ten minutes at their own self-selected walking speed (7) while 3D kinematics of both feet from the straight line walking (reflective markers placed on the calcaneus of each foot) were only recorded using optical motion capture (VICON, OMG Ltd, UK). Table 2 . Unfortunately, only 45% of the included studies used 50 or more steps in their analysis, which might be required for reliable assessment of gait variability (7) .
Since 2014 when the previous review was conducted, nine additional studies included STV in their trials, an increase of ~24%, hence necessitating an update of the reported thresholds between healthy asymptomatic and pathological variability. In the current study, we evaluated the higher bound of physiological STV to be 2.34%, which is 0.26% lower than the estimate in the original review. The delta method was then employed to identify the standard error in the likelihood estimates as ±0.21%. The corresponding 95% confidence intervals (95%CIs) for the upper thresholds of physiological stride time variability were thus estimated as 1.92 -2.76% (2 SDs above and below the mean). Similar to STV, the optimal thresholds and subsequently the likelihood estimates were also evaluated for the other commonly reported gait parameters ( Table   1) Supplementary Table 3 ). Finally, the funnel plot reporting bias (reduced likelihood of studies being published that report negative or no ESs).
Schematic representation of optimal thresholds data using radar plots:
The patients suffering from basal ganglia disorders (Parkinson's as well as Huntington's disease - 
Discussion
Movement variability is an important characteristic that may represent both redundancy and adaptability of human task performance (24, 27, 44) . Recent investigations clearly demonstrate that MoV is sensitive to adaptations, including learning new skills (45, 46) , the onset of movement disorders (22, 23, 26, 47) and response to therapies (10, (48) (49) (50) . Despite this overwhelming evidence, there has been limited uptake of MoV in clinical settings. Contemporary reports (7, 24, 26, 36) suggest that primary reasons for such a discrepancy are: i) a lack of understanding and misconceptions associated with MoV -e.g. MoV might represent error, but is also associated with adaptability (51, 52), ii) a subjective bias together with an arbitrary choice of parameters, and iii) the general requirement for dedicated measurements during extended periods of walking to effectively estimate MoV (7) . Despite the use of 4-and 6-minute walk tests in clinical settings, the continued lack of comprehensive assessment of gait quality suggests an opportunity missed, and perhaps a disadvantage to both the individual patient and the health care system. The evidence from this systematic review of the literature clearly suggests that MoV is able to quantify gait quality, furthermore the probabilistic analysis revealed an optimum threshold between healthy asymptomatic and pathological gait patterns. As such, there is potential added value of complementing standard clinical assessments with the evaluation of MoV as a relevant movement biomarker for identifying subjects with early signs of disease, but also in monitoring adaptations after therapy. One of the principal challenges hindering the uptake of MoV has been the need to collate the wealth of diverse literature, and provide a clear understanding of the healthy physiological levels of variability during walking. This study has therefore directly provided numerical evidence on healthy physiological movement performance, suggesting that locomotor tasks within populations suffering from neurological disorders might be distinctly regulated from their healthy asymptomatic counterparts (22, 24, 27) .
A previous literature-based meta-analysis that investigated STV, provided optimum thresholds for establishing the limits between healthy asymptomatic and pathological task performance (26) . Due to the lack of both large-scale as well as long-term assessments, this numerical evidence was plausibly subject to change with new literature appearing. A preliminary search gauged and confirmed the existence of substantial new evidence, which therefore J o u r n a l P r e -p r o o f necessitated this review update (53) . To accommodate such changes, a probabilistic approach to evaluate the boundaries for healthy performance in walking behaviour was considered within this updated review. The CI of the upper threshold of 2.34 %CV ranged from 1.92-2.76 %CV, and provides a robust probabilistic estimate for handling any new evidence on STV. An STV larger than this threshold, and certainly one exceeding the CI's upper boundary, indicates an overall inability to maintain temporal consistency of foot placement, such that walking performance might, in general, be closer to the limits of stability (2, 22) . Specifically, an inter-cycle STV larger than the threshold might lead to inconsistency between swing and stance phases of gait making it difficult to maintain the CoM of the body within the base of support across cycles. Such an estimate therefore provides a meaningful threshold for objectively assessing STV and highlighting its value for clinical uptake for the purposes of screening individuals that might suffer from movement impairments.
In the interest of translation to clinical settings, an important question is: "Does STV -the single most commonly used parameter of MoV -have the necessary attributes to qualify as a gait biomarker for detecting movement disorders? Here, Hausdorff (24) has proposed that for
MoV to be used as a biomarker, its reliability, accuracy, sensitivity and clinical utility (time-and cost-effectiveness) should all be established, or an optimal trade-off between all these attributes should be found. The duration of walking trials has a substantial effect on the reliability of assessing kinematic variability (54) , but STV has also been shown to be modestly reliable with 50 steps, resulting in an inter-day test-retest variability of ∼13% (7) . This systematic review revealed that STV had a large effect size with the lowest standard errors for discriminating healthy asymptomatic vs. pathological performance (Table 1 ). Furthermore, the logistic regression model based on population data revealed that there is clearly a high level of sensitivity and specificity (75%) for using STV alone to identify movement disorders, proving its predictive capability (Table   1 ). Benchmarking demonstrated robust levels for higher bounds of unstable walking performance, providing the much-needed impetus for the practical uptake of STV in clinical settings towards accurately identifying individuals that suffer from movement impairments.
Finally, although direct evidence of clinical utility of STV remains lacking, the metric is seemingly well-accepted and incorporated in many clinical trials as a primary (37) or secondary outcome J o u r n a l P r e -p r o o f measure (40, 48) . Notably, a Phase II clinical trial has recently used step time variability as a surrogate marker to investigate gait stability and fall risk in PwPD (55) . Finally, the accessibility of this parameter from wearable technologies clearly promotes STV as a promising signature for assessing movement rhythmicity. Recent evidence indicates that multiple signatures are modulated differently by age (57), pathology (25, 58) , walking speed (59), gender (60) , but more importantly also by complex interactions between one or more of these factors (e.g. for age and walking speed see (61, 62) ).
Although we did not observe a considerable effect of age on the overall effect size (or on stride time variability undertaken in separate subgroup analyses - Supplementary Tables 4 & 5) , the modulatory effects of walking speed or gender could not be explored within this meta-analysis J o u r n a l P r e -p r o o f due to the lack of availability of data within the original studies. Despite this discrepancy, the meta-analysis clearly provides evidence on optimal boundaries for variability of multiple commonly identified spatio-temporal parameters.
Of all the parameters reported, step width variability was the only metric to exhibit reduced levels of variability in pathological populations compared to healthy asymptomatic individuals. This result is consistent with the original systematic review (26) and coherent to previous findings that diminished step width variability is linked to poor balance and fall risk (63) .
On the neuromotor level, this observation plausibly indicates tightening control in one dimension at the expense of another. The significance of this finding however, needs further exploration and should be interpreted with caution, especially in the context of its dynamic interplay with both centre of mass kinematics (64, 65) , but also STV during task execution (66) . In fact, variability in step width reflects the regulation of the body's base of support in order to maintain balance in the medio-lateral direction during walking. Biomechanically, modifications to step width (e.g.
extending the lateral margins of the base of support -see 2, 65, 67) and/or double limb support time (extended time period during which the projected CoM is within the base of support) might influence our balance during walking (25, 28, 35, 68, 69) . Moreover, step width might be regulated on a cycle-to-cycle basis and is intricately related to the walking speed (62, 70) , the kinematic state of the CoM (2), but also the energy requirements (71, 72) as well as other environmental constraints. Although step width as well as dual limb support time have been suggested to reflect balance control (2, 65, 67) , the number of studies that reported step width variability (as well as dual limb support time variability) are approximately 9 times lower than those reporting STV.
Despite widespread access to wearable technologies that allow the assessment of temporal parameters, their inability to assess spatial parameters such as step width is one of, if not the 
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The hypothesis of dynamic interplay between movement or gait signatures (but also relevant as independent domains), such as that between rhythmicity and balance control, highlights the need for comprehensive assessment of movement performance in future over the more conservative and commonplace subjective approach of pre-selecting parameters in an arbitrary manner. Here, we support the necessity of assessing a family (for similar approach please also see (73)) of gait signatures including but not limited to rhythmicity, balance, coordination, regularity (the predictability of movement), asymmetry (motor and/or physical symptom leading to discrepancy between parameters from two limbs) and obstacle avoidance.
In fact, results presented here provide preliminary evidence that movement disorders affecting different regions of the brain (i.e. Parkinson's vs. Alzheimer's disease) might influence different signatures (cf. Figure 4b vs. c). Such representation therefore clearly indicates how presenting boundaries for multiple parameters enables rapid determination of a particular motor deficit, but also allows comparison across different disease groups. In future an operational model, which provides an unbiased statistical/data-lean presentation to extract the most important signatures, would be a preferred approach that will allow clinicians to characterize complex distinctive walking behaviours in both healthy asymptomatic and pathological individuals. Such an approach could incorporate multivariate methods to rank the important signatures from kinematic data, while simultaneously allowing the identification of interplay between the signatures.
Consequently, it would also make way for multivariate classification models using population based optimal estimates, which until now has not been available. Establishing and benchmarking movement signatures with population based optimal estimates as has been undertaken in this review will allow generalized estimates of MoV to provide scalable and unbiased information on movement quality.
Finally, we have reported a preliminary approach to characterize motor impairments in subjects with movement disorders based on population-based evidence derived from the metaanalysis. The usage of this approach has been demonstrated in an exemplary case study comprising PwPD (Figure 4 (Table 1 ), e.g. 1.92 -2.76%CV as uncertainty for the upper threshold of 2.34 %CV for STV, such that we have an effective and rapid screening of movement performance. Further studies are necessary to explore the broader utility and potential biases of our approach (utilizing optimum thresholds obtained through meta-analyses based on aggregate data to benchmark individual's movement quality might not be always straightforward).
Nevertheless, our robust meta-analytic approach will allow the uptake of objective metrics on signatures within clinical information, a concept that is extremely important, but is not well appreciated until now (73) .
Overall, when viewed from a human sensory motor control perspective, a neurophysiological approach that collates all available evidence-based clinical information in a that quantitative motor performance data (also in the form of pooled population information available through this review) can be utilized for developing gait hypermodels (such as the one proposed in this paper) with a vision for benchmarking behaviour, developing biomarkers and understanding neuro-adaptive behaviour of aged and pathological populations.
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